LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Inicio・Lista de Acciones・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Cerrado

SectorSanidad

32.9 -5.05

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

32.58

Máximo

34.65

Métricas clave
By Trading Economics
Ingresos	-5M -128M
Ventas	6.8M 11M
BPA	-1.23
Margen de beneficios	-1,191.029
Empleados	594
EBITDA	-18M -139M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+154.52% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-710M 3.6B
Apertura anterior	37.95
Cierre anterior	32.9

Noticias sobre sentimiento de mercado

By Acuity

94%

1 / 344 Clasificación en Healthcare

Crinetics Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 19:20 UTC

Principales Movimientos del Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 jun 2026, 21:27 UTC

Ganancias

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Charlas de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Charlas de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Charlas de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Charlas de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Adquisiciones, fusiones, absorciones

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Ganancias

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 15:44 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 15:26 UTC

Charlas de Mercado

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 jun 2026, 15:25 UTC

Ganancias

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 jun 2026, 15:16 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 15:16 UTC

Charlas de Mercado

Zcash Tumbles After Exploit Found -- Market Talk

5 jun 2026, 15:09 UTC

Charlas de Mercado

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 jun 2026, 15:07 UTC

Charlas de Mercado

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 jun 2026, 15:05 UTC

Charlas de Mercado

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparación entre iguales

Cambio de precio

Crinetics Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

154.52% repunte

Estimación a 12 Meses

Media 88.14 USD 154.52%

Máximo 97 USD

Mínimo 81 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

1 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.